$LXU

Ackerman Jonathan Z. purchased $10K of LXU

Ackerman Jonathan Z. purchased 1,000 shares of LSB INDUSTRIES, INC. (LXU) at $9.89 on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ackerman Jonathan Z.
Published Aug 13, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LXU
Neutral
low confidence
Mentioned
$LXU
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LXUNeutralLow
01

Why it matters

The newest fact is the specific open-market purchase details (1,000 shares at $9.8900) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

A routine, small 10b5-1 insider buy is unlikely to change valuation expectations on its own.

03

What to watch

Traders may over-weight small insider buys; the more actionable signal would be larger, non-10b5-1 insider activity or operational/regulatory updates.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-13 after-hours; transaction dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction filing for LSB Industries, Inc. (LXU).

Company-level read

Ticker impact

$LXUNeutralLow confidence
Context

LSB Industries director Jonathan Z. Ackerman filed a Form 4 open-market purchase of 1,000 shares at $9.8900 on 2026-08-12.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

The disclosure is a routine insider transaction, the size is modest ($9,890), and it is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive power.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Because the buy is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity or diversification rather than a new bullish view.

Key entities

  • LSB Industries, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Jonathan Z. Ackerman

    Director who purchased 1,000 shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LXUMedAI 8/10

LSB Industries (LXU) Q2 2026 Earnings Call Transcript

LSB Industries (LXU) reported Q2 2026 net sales of $168.1 million, up 11.1% from $151.3 million, with adjusted EBITDA of $53.1 million, up 38.8%. The quarter included a $6.2 million net loss tied to $28.8 million in turnaround expenses and $35 million to $40 million of maintenance impact. Management cited El Dorado turnaround completion, ammonia and carbon capture plans, and $218 million cash.

$LXUMed

LSB INDUSTRIES, INC. REPORTS OPERATING RESULTS FOR THE 2026 SECOND QUARTER

LSB INDUSTRIES, INC. (LXU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LSB INDUSTRIES, INC. REPORTS OPERATING RESULTS FOR THE 2026 SECOND QUARTER OKLAHOMA CITY, Oklahoma—July 29, 2026— LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the second quarter ended June 30, 2026. Second

$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).